Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Jackman on Benefits of Liquid Biopsies in Lung Cancer

February 3rd 2017

David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the benefits of liquid biopsies for patients with lung cancer.

Dr. Socinski on Challenges Facing Immunotherapy Combinations

February 3rd 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses challenges facing immunotherapy combinations in patients with non–small cell lung cancer (NSCLC).

Dr. Weiss on Disease-Control Rate of Immunotherapy for Lung Cancer

February 1st 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy as treatment to control disease for patients with lung cancer.

EC Approves Frontline Pembrolizumab for PD-L1+ Metastatic NSCLC

February 1st 2017

The European Commission has expanded the indication for pembrolizumab to include the frontline treatment of patients with metastatic non–small cell lung cancer that expresses PD-L1 on ≥50% of cells and does not harbor an EGFR or ALK mutation.

Future Directions for ALK+ NSCLC

January 31st 2017

Emerging ALK/ROS1 TKIs for NSCLC

January 31st 2017

Upfront Use of Second-Generation TKIs in ALK+ NSCLC

January 31st 2017

ASCEND-4: Upfront Ceritinib in ALK-Rearranged NSCLC

January 31st 2017

ALK Inhibitor Sequencing in NSCLC

January 31st 2017

Mutation Testing to Guide ALK TKI Selection in NSCLC

January 31st 2017

Choosing Second-Line Therapy for ALK+ NSCLC

January 31st 2017

Alectinib for Relapsed/Refractory ALK+ NSCLC

January 31st 2017

Ceritinib Alternative Dosing for ALK+ NSCLC

January 31st 2017

Experience with Ceritinib for ALK+ NSCLC

January 31st 2017

Ceritinib and Alectinib in Relapsed ALK+ NSCLC

January 31st 2017

Crizotinib Resistance in ALK+ NSCLC

January 31st 2017

The Evolution of ALK/ROS1-Targeted TKIs

January 31st 2017

Anti-PD-1/PD-L1 Immunotherapy in Lung Cancer: Update From the ESMO 2016 Congress

January 31st 2017

Lung cancer is the leading cause of cancer-related deaths among men and women in the United States, despite being the second most commonly diagnosed cancer.

Dr. Weiss on PD-L1 Biomarker in Lung Cancer

January 30th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.

Frontline Immunotherapy Combo Setbacks Strike NSCLC

January 21st 2017

Bristol-Myers Squibb and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.